Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Винорелбин в терапии немелкоклеточного рака легкого

https://doi.org/10.33667/2078-5631-2021-10-8-15

Полный текст:

Аннотация

Химиотерапия продолжает оставаться неотъемлемой частью системного лечения немелкоклеточного рака легкого (НМРЛ), а винорелбин доказал эффективность в адъювантной терапии в составе химиолучевых программ и в лечении метастатической формы заболевания. Пероральная форма препарата отличается значительно бóльшим удобством применения и может использоваться не только в стандартных режимах дозирования (как в монотерапии, так и в комбинации с производными платины), но и в метрономной терапии, предусматривающей более частый прием винорелбина в меньших разовых дозах. Пероральный винорелбин доказал высокую эффективность и безопасность в различных популяциях пациентов, включая подгруппы пожилых и ослабленных больных, и может широко использоваться на различных этапах лечения НМРЛ. 

Об авторе

Е. В. Артамонова
ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Блохина» Минздрава России; ФГAOУ ВО «Российский национальный исследовательский медицинский университет имени И. И. Пирогова» Минздрава России
Россия

Артамонова Елена Владимировна, д.м.н., зав. химиотерапевтическим отделением № 1; проф. кафедры

Москва



Список литературы

1. Горбунова В. А., Артамонова Е. В., Бредер В. В., Лактионов К. К., Моисеенко Ф. В., Реутова Е. В., Сакаева Д. Д. Практические рекомендации РУССКО по лекарственному лечению немелкоклеточного рака легкого. (НМРЛ) Версия 2020. Злокачественные опухоли. 2020. С. 22–36. Gorbunova V. A., Artamonova E. V., Breder V. V., Laktionov K. K., Moiseenko F. V., Reutova E. V., Sakaeva D. D. Practical RUSSIAN recommendations for drug treatment of non-small cell lung cancer. (NSCLC) Version 2020. Malignant tumors. 2020. P. 22–36.

2. Alatar ML, Gold KA, Kim ES. Evolving treatment paradigms in Non-Small Cell Lung Cancer. Clinical Oncology 2009; 12, N 2: 29–43.

3. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016; 375 (19): 1823–1833.

4. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced NSCLC with PD-L1 TS > 50 %. WCLC 2017, OA 17.06, presented 18.10.2017.

5. Brahmer JR, Rodríguez-Abreu D, Robinson AG, et al. Progression after the next line of therapy (PFS 2) and updated OS among patients with advanced NSCLC and PD-L1 TPS > 50 % enrolled in KEYNOTE-024. ASCO 2017, abstract 9000.

6. Тюляндин С. А., Имянитов Е. Н., Моисеенко В. М. и др. Терапия больных немелкоклеточным раком легкого в российской федерации: исследование EPICLIN-LUNG. Современная онкология. 2016. Т. 18. № 4. С. 27–33. Tyulyandin S. A., Imyanitov E. N., Moiseenko V. M. et al. Therapy of patients with non-small cell lung cancer in the Russian Federation: the EPICLIN-LUNG study. Modern Oncology. 2016. Vol. 18. No. 4, pp. 27–33.

7. Lee Ch. Kh., Man J., Lord S., et al. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non–Small Cell Lung Cancer – A Meta-Analysis. Journal of Thoracic Oncology Vol. 12, 2017, No. 2: 403–407.

8. Mazières J, Drilon A., Lusque A., et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30 (8): 1321–28.

9. Goss GD et al., ASCO 2010, abstr. 7005. (adjuvant gefitinib)

10. Altorki NK, et al. Chicago Multidisciplinary Symposium in Thoracic Oncology 2014. Abstract 4. (RADIANT)

11. ASCO 2017 abstr 8500 (adjuvant gefitinib)

12. Yi-Long Wu, Wen-Zhao Zhong, Qun Wang, et al. CTONG 1104: adjuvant gefitinib versus chemotherapy for resected N 1–N 2 NSCLC with EGFR mutation – final overall survival analysis of the randomized phase 3 trial. ASCO 2020 – abstr. 9005.

13. Chansky K, et al. IASLC WCLC 2009. Abstract B 2.7.

14. Moro-Sibilot D, Smit E, de Castro Carpeno J, et al. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study. Lung Cancer 20156 V 88 (Issue 2): 215–222.

15. De Lena M, Ramlau R, Hansen O et al. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC. Lung Cancer 2005; 48: 129–135.

16. Tan EH, Rolski J, Grodzki T, et al. Global Lung Oncology Branch trial 3 (GLOB 3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals Oncology 2009; 20: 1249–1256.

17. Tan EH et al. Oral Vinorelbine and cisplatin or pemetrexed as first-line chemotherapy for non squamous metastatic or locally advanced non small cell lung cancer: Final results of a prospective randomised phase II trial (NAVoTrial). WCLC 2013.

18. Bennouna J, Havel L, Krzakowski M, et al. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: Final results of an international randomized phase II study (NAVotrial 01). Clinical Lung Cancer 20144, Vol. 15, No. 4, 258–65.

19. E H Tan, A Szczesna, M Krzakowski, et al. Randomized study of vinorelbine – gemcitabine versus vinorelbine – carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005 Aug; 49 (2): 233–40.

20. Flotten O., Grønberg BH, Bremnes RM, et al. Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2012 Jul 24; 107 (3): 442–447.

21. Pallis AG, Syrigos K, Kotsakis A, et al. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. Clin Lung Cancer. 2011; 12(2): 100–5 (ISSN: 1938–0690).

22. Gridelli C, Manegold C, Mali P, et al. Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: A multicentre phase II trial. European Journal of Cancer 2004, V 40 (Issue 16), P 2424–2431.

23. Kerbel RS. Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective. Ed. G. Bocci and G. Francia. Metronomic Chemotherapy: Pharmacology and Clinical Applications. Berlin: Springer-Verlag; 2014: 3–21.

24. Kerbel RS, Kamen BA. Nat Rev Cancer 2004; 4: 423–36.

25. Cazzaniga ME, et al. Future Oncol 2016; 12 (3): 373–87.

26. Briasoulis E, Pappas P, Puozzo C, Tolis C, Fountzilas G, Dafni U, et al. Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer. Clin Cancer Res 2009; 15: 6454–61.

27. Rajdev L, Negassa A, Dai Q, Goldberg G, Miller K, Sparano JA. Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol 2011; 68: 1. 119–24.

28. Biziota E, et al. Anticancer Drugs. 2016; 27 (3): 216–24.

29. Mavroeidis L, et al. J Clin Oncol. 2015; 47 (2): 455–64.

30. Alizadeh D, Larmonier N. Cancer Res. 2014; 74 (10): 2663–8.

31. Ghiringhelli F, et al. Cancer Immunol Immunother. 2007; 56 (5): 641–8.

32. Camerini A, Puccetti Ch, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer 2015; 15: 359.

33. Gusella M, Pasini F, Caruso D, et al. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR 1 polymorphisms. Cancer Chemotherapy and Pharmacology, 2019, Volume 83, Issue 3, pp. 493–500.

34. D’Ascanio M, Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A, et al. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced NonSmall Cell Lung Cancer. Biomed Res Int. 2018; 2018: 6278403. https://pubmed.ncbi.nlm.nih.gov/30225260/ DOI: 10.1155/2018/6278403.

35. Estevino F., Gomes R., Hasmucrai D., Barata F. Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients. Pulmonology 2020. https://doi.org/10.1016/j.pulmoe.2020.09.003

36. Zhu Q, Zhang J, Liu J and Song B. Advances in oral vinorelbine metronomic chemotherapy for non-small cell lung cancer. Clin Oncol 2018; 3: 1550.

37. A. Vergnenegre, G. Robinet, C. Chouaid, et al. VinMetAtezo: phase II trial of metronomic oral vinorelbine with atezolizumab for recurrent stage IV NSCLC GFPC (French Lung Cancer Group): 04–18. World Conference on Lung Cancer 2019, Session P2.01, Abstr 690.

38. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non-Small-Cell Lung Cancer. N Engl J Med 2004; 350: 351–60.

39. Butts Ch A, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: Updated survival analysis of JBR-10. Journal of Clinical Oncology, Volume 28, Issue 1, 1 January 2010, Pages 29–34.

40. Douillard J.Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (ANITA): a randomized controlled trial. Lancet Oncol. 2006: 7: 719–727.

41. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20; 26 (21): 3552–9.

42. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol. 2010 Feb; 5 (2): 220–8.

43. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med 2004; 350: 351–360.

44. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N. Engl. J. Med 2005; 352: 2589–2597.

45. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-celllung cancer. J. Clin. Oncol. 2012; 30: 172–178.

46. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association (ANITA): a randomized controlled trial. Lancet Oncol 2006; 7: 719–727.

47. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage Ib and II non – small-cell lung cancer: updated survival analysis of JBR-10. JCO 2010; 28 (1): 29–34.

48. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 208; 26: 3552–3559.

49. Kolek V. et al. Oral vinorelbine in combination with carboplatin in adjuvant chemotherapy of non-small cell lung can-cer: a prospective multicentre study of feasibility and tolerability. WCLC 2013.

50. Engel-Riedel et al. Adjuvant treatment of completely resected stage IB-IIIA non-smallcell lung cancer – a retro-spective study with cisplatin or carboplatin and oral vinorelbine. ESMO 2013, #3428.

51. Kolek V, Grygarkova I, Koubkova L, et al. Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell lung cancer in real-world set-up. Plos One July 21, 2017. https://doi.org/10.1371/journal.pone.0181803

52. Kolek V. Contemporary Trends of the Adjutant Chemotherapy in Non-small Cell Lung Cancer.Klin Onkol 2013; 26 (4): 245–50. doi: 10.14735/amko2013245. www. researchgate.net/publication/256073622_Contemporary_Trends_of_the_Adjutant_Chemotherapy_in_Non-_small_Cell_Lung_Cancer

53. Kolek V. Losse S, Kultan J, et al. Real life adjuvant chemotherapy uptake and survival in patients with non-small-cell lung cancer after complete resection. Current Medical Research and Opinion, DOI: 10.1080/03007995.2018.1490254. https://doi.org/10.1080/03007995.2018.1490254

54. Postmus PE, Kerr KM, Oudkerk M, et al. Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Annals Oncology 2017, 28 (suppl 4): iv1–iv21.

55. Vokes EE, Herndon JE II, Crawford J, et al. Randomized Phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherap for stage IIIb non-small cell lung cancer: cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20: 4191.

56. Krzakowski, MD, Mariano Provencio, MD, Beata Utracka-Hutka, et al. Oral Vinorelbine and Cisplatin as Induction Chemotherapy and Concomitant Chemo-Radiotherapy in Stage III Non-small Cell Lung Cancer Final Results of an International Phase II Trial. Journal of Thoracic Oncology 2008 Volume 3, Number 9 P. 994–1002.

57. Vansteenkiste J, De Ruysscher D, Eberhardt WEE, et al. Early and Locally Advanced Non-Small-Cell Lung Cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013 Volume 24, Issue suppl 6, October 2013, Pages vi89–vi98.

58. Hsu P-Ch, Chang J W-Ch, Wang Ch-Ch, et al. Oral vinorelbine plus cisplatin with concomitant radiotherapy as indaction therapy for stage III non-small cell lung cancer: results of a single-arm prospective cohort study. Thoracic Cancer 10 (2019) 1683–1691. DOI: 10.1111/1759–7714.13125.

59. Isla D, De Las Penas R, Marse R, et al. Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo-Radiation in Stage III NSCLC. SLCG 10/022018. MA06709 Abstr S 373.


Для цитирования:


Артамонова Е.В. Винорелбин в терапии немелкоклеточного рака легкого. Медицинский алфавит. 2021;(10):8-15. https://doi.org/10.33667/2078-5631-2021-10-8-15

For citation:


Artamonova E.V. Vinorelbine in treatment of non-small cell lung cancer. Medical alphabet. 2021;(10):8-15. (In Russ.) https://doi.org/10.33667/2078-5631-2021-10-8-15

Просмотров: 18


ISSN 2078-5631 (Print)